Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400334 · ClinicalTrials.gov registry record
Prediction of ARrhythmic Events With Positron Emission Tomography
A clinical trial of Ischemic Cardiomyopathy and Hibernating Myocardium, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 257
- Enrollment target
- 1
- Study location
NCT01400334: Completed study of Ischemic Cardiomyopathy and Hibernating Myocardium, sponsored by State University of New York at Buffalo.
NCT01400334 is a study of Ischemic Cardiomyopathy and Hibernating Myocardium that has completed, run by State University of New York at Buffalo. The registered enrollment target is 257 participants, below the 353-participant average among 10 other Ischemic Cardiomyopathy trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01400334, a study of Ischemic Cardiomyopathy and Hibernating Myocardium, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 257 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of PAREPET is that hibernating myocardium (viable myocardium with reduced resting flow) and/or viable but denervated myocardium can predict the risk of sudden death in subjects with ischemic cardiomyopathy.
Primary Outcome
Adjudicated sudden cardiac death and implantable cardiac defibrillator therapy for fast ventricular tachycardia (\>240 bpm) or ventricular fibrillation.
Conditions Studied
Interventions
- RADIATION Positron Emission Tomography
Study Locations (1)
New York
- SUNYBuffalo - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 257 participants |
| Start Date | 2004-07 |
| Est. Completion | 2012-12 |
What the finished NCT01400334 record still lists
NCT01400334 is an observational study that tracks outcomes without assigning an intervention. The registered 257 participants enrollment target is mid-sized for trials with a published cap, below the 353-participant average among 10 other Ischemic Cardiomyopathy trials with a reported enrollment target (27% lower).
The record links to 3 conditions, with Ischemic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Positron Emission Tomography is the first listed.
NCT01400334 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01400334 about?
NCT01400334 is a clinical study titled "Prediction of ARrhythmic Events With Positron Emission Tomography". The hypothesis of PAREPET is that hibernating myocardium (viable myocardium with reduced resting flow) and/or viable but denervated myocardium can predict the risk of sudden death in subjects with ischemic cardiomyopathy.
What is the current status of trial NCT01400334?
This trial is currently completed. The enrollment target is 257 participants. The study started on 2004-07. Estimated completion is 2012-12.
What conditions does trial NCT01400334 study?
This clinical trial studies the following conditions: Ischemic Cardiomyopathy, Hibernating Myocardium, Nerve; Disorder, Sympathetic.
What interventions are being tested in trial NCT01400334?
The interventions under investigation include: Positron Emission Tomography (RADIATION).
Who is sponsoring clinical trial NCT01400334?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01400334 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01400334's enrollment target sits among peer trials
257 6th of 10 higher than 5 of 10 other Ischemic Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ischemic Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Left Ventricular Structural Predictors of Sudden Cardiac Death
RECRUITING
-
Implantable Cardioverter Defibrillator (ICD Registry)
RECRUITING
-
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
RECRUITING · NA
-
Phenotypic Classification of FMR With CMR
RECRUITING
-
Venous Ethanol for Ventricular Tachycardia
RECRUITING · Phase 2
-
Impella Supported OPCABG
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03618550 · 257 participants · Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- NCT04674267 · 257 participants · NA
Resilience and Equity in Aging, Cancer, and Health (REACH)
- NCT06099288 · 257 participants · NA
Strong Families Start at Home/Familias Fuertes Comienzan en Casa
- NCT06207084 · 257 participants · NA
The Fit With Us Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia